[go: up one dir, main page]

Slosman et al., 1997 - Google Patents

Cerebral Spect Imaging: Advances in Radio Pharmaceuticals and Quantitative Analysis

Slosman et al., 1997

Document ID
246891638246397886
Author
Slosman D
Magistretti P
Publication year
Publication venue
Alzheimer Disease: From Molecular Biology to Theraphy

External Links

Snippet

For more than a decade, nuclear medicine has been recognized as the unique tool for performing functional brain imaging and for quantifying non-invasively regional cerebral blood flow (rCBF). It required high-cost technology, such as positron emission tomography …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/50—Clinical applications
    • A61B6/507—Clinical applications involving determination of haemodynamic parameters, e.g. perfusion CT

Similar Documents

Publication Publication Date Title
Okada et al. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile.
Narra et al. A neutral technetium-99m complex for myocardial imaging
Walovitch et al. Characterization of technetium-99m-L, L-ECD for brain perfusion imaging, Part 1: Pharmacology of technetium-99m ECD in nonhuman primates
Innis et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.
Volkert et al. 99mTc-propylene amine oxime (99mTc-PnAO); a potential brain radiopharmaceutical
Mathias et al. Evaluation of a potential generator-produced PET tracer for cerebral perfusion imaging: single-pass cerebral extraction measurements and imaging with radiolabeled Cu-PTSM
Seibyl et al. Test/retest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson's patients
Poe et al. Myocardial Imaging with 123l-Hexadecenoic Acid
Rottenberg et al. In vivo measurement of brain tumor pH using [11C] DMO and positron emission tomography
Mazière et al. In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br] bromospiperone
Walsh et al. Nitrogen-13-labeled ammonia for myocardial imaging
Wallhaus et al. Human biodistribution and dosimetry of the PET perfusion agent copper-62-PTSM
Lear Quantitative local cerebral blood flow measurements with technetium-99m HM-PAO: evaluation using multiple radionuclide digital quantitative autoradiography
Fischman et al. Regional measurement of canine skeletal muscle blood flow by positron emission tomography with H2 15O
US20180271470A1 (en) Methods for quantifying pancreatic beta cell function and mass properties with radiomanganese positron emission tomography
Adelstein et al. Radioindicators for the study of the heart: principles and applications
Slosman et al. Cerebral Spect Imaging: Advances in Radio Pharmaceuticals and Quantitative Analysis
Mossberg et al. Skeletal muscle blood flow in vivo: detection with rubidium-82 and effects of glucose, insulin, and exercise
Magistretti QUANTITATIVE ANALYSIS
Tsuchida et al. Quantification of regional cerebral blood flow with continuous infusion of technetium-99m-ethyl cysteinate dimer
Kung et al. Preparation and biodistribution of [125I] IBZP: a potential CNS D-1 dopamine receptor imaging agent
Dischino Development of positron emitting brain perfusion agents
Pandey et al. Formulation and evaluation of a two-components lyophilized kit for Tc-sestamibi: transchelation preparation of Tc-99m-sestamibi
Popescu et al. In vivo labelling of RBC with 99mTc for blood pool imaging using different stannous radiopharmaceuticals
Williams et al. 99mTc-Labelled serum albumin in cardiac output and blood volume studies